FRMPD2B
Putative protein FRMPD2-like
Also known as: FRP2L_HUMAN
Protein identityUniProt · HPA
OverviewNCBI Gene
No narrative summary is available for FRMPD2B in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
320 residues, UniProt reviewed canonical sequence.
>Q6IN97|FRMPD2B
1 MTSIPFPGDR LLQVDGVILC GLTHKQAVQC LKGPGQVARL VLERRVPRST QQCPSANDSM
61 GDERTAVSLV TALPGRPSSC VSVTDGPKFE VKLKKNANGL GFSFVQMEKE SCSHLKSDLV
121 RIKRLFPGQP AEENGAIAAG DIILAVNGRS TEGLIFQEVL HLLRGAPQEV TLLLCRPPPG
181 ALPEMEQEWQ TPELSADKEF TRATCTDSCT SPILDQEDSW RDSASPDAGE GLGLRPESSQ
241 KAIREAQWGQ NRERPWASSL THSPESHPHL CKLHQERDES TLATSLEKDV RQNCYSVCDI
301 MRLGRYSFSS PLTRLSTDIFLocalizationUniProt · AlphaFold · HPA
Whether an antibody against FRMPD2B can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.54
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads FRMPD2B as an antibody target. Whether an autoantibody or antibody against FRMPD2B could matter depends on whether native FRMPD2B is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
FRMPD2B is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label FRMPD2B as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...